Tonic for Abbvie on first day of trading in New York
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The pharmaceutical firm Abbott Laboratories and its spin-off AbbieVie toasted a strong start to the New Year in their first day trading as an independent businesses.
Richard Gonzalez, the chairman and chief executive of AbbVie, rang the opening bell on the New York Stock Exchange and both companies saw their shares rise in early trading yesterday.
After the split from the larger Abbott, Abbvie will employ 400 staff in Ireland and 21,000 people globally, with estimated annual revenues of $18bn from its products for rheumatoid arthritis and testosterone.
Mr Gonzalez said said: "AbbVie launches with an outstanding portfolio."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments